Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Only the lactation uncertainty/absence-of-data statements can be supported by the provided label excerpt (Section 8.2). Key effectiveness/indication claims cannot be verified because Section 1 text was not provided, and several claims rely on mechanistic inference or stronger-than-labeled language (e.g., milk passage inference, and asserting no published studies rather than “no data in human milk”).
Category Scores
Accurate Statements
The extent of lurbinectedin passage through breast milk is unknown.
Supported by Section 8.2 Lactation: "There are no data on the presence of lurbinectedin in human milk..."
The extent of lurbinectedin passage through breast milk is unknown.
Supported by Section 8.2 Lactation (no human-milk presence data).
Further research is needed to confirm whether lurbinectedin is present in breast milk.
Consistent with Section 8.2 Lactation: absence of data on presence in human milk.
Unsupported Statements
Lurbinectedin is used to treat relapsed or refractory small cell lung cancer (SCLC).
The provided materials do not include Section 1 (Indications and Usage), so the specific indication cannot be verified from label text.
Lurbinectedin is used to treat other types of cancer.
No indication information beyond Section 1 is provided; cannot verify from supplied label excerpts.
Lurbinectedin is a lipophilic compound.
Section 11 Description excerpt provided does not state lipophilicity; cannot be supported from supplied label text.
Because lurbinectedin is lipophilic, it may be able to pass through breast milk.
This is a mechanistic inference not stated in Section 8.2 Lactation; label excerpt only addresses presence/effects data and breastfeeding advice.
There are no published studies specifically investigating the passage of lurbinectedin through breast milk.
Section 8.2 states there are no data on presence in human milk, which does not necessarily support the stronger claim about lack of published studies on “passage” specifically.
A related compound (PM01182333) was present in breast milk at low concentrations.
No information about PM01182333 appears in the provided label excerpts.
This suggests that lurbinectedin may also be present in breast milk.
Section 8.2 Lactation does not make this inference; it states there are no data on presence in human milk.
Contradictions
Important Omissions
Verification of Section 1 Indications and Usage details (including relapsed/refractory SCLC wording) is not possible because Section 1 label text was not provided.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Indication-related claims are unverified due to missing Section 1 label text, and mechanistic/more-specific breastfeeding-passage claims are not supported by the provided lactation excerpt. However, no dosing or contraindication statements were made that could directly cause unsafe medication use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several statements are not supported by the supplied label excerpts (missing Section 1 for indications; unsupported mechanistic inference and stronger-than-labeled evidentiary claims for breastfeeding milk passage; unrelated compound PM01182333 not present in provided label).
Suggested Improvement
Limit lactation statements to what Section 8.2 supports (no data on presence/effects; breastfeeding avoidance during treatment and for 2 weeks after last dose). Remove mechanistic “lipophilic → milk passage” inference and the claim about “no published studies” unless Section 8.2 explicitly states that. Provide Section 1 text to verify the exact indication wording.